Keywords
CURRENT study
Argentina
real-world evidence
How to Cite
Abstract
Introduction: patients with acute myeloid leukemia unfit for intensive chemotherapy were historically treated with hypomethylating agents (HMA), low-dose cytarabine (LDAC) or best supportive care (BSC) before venetoclax approval. Materials and methods: to describe real-world treatment patterns and clinical outcomes, we performed a subanalysis of 77 patients from Argentina who participated in the worldwide CURRENT study, initiating treatment between 2015 and 2018 (before venetoclax approval; cutoff: 3/31/2020). Results: median age at diagnosis was 75 years. Proportion of BSC-only patients was higher, compared with global data. Relative proportion of patients with high-risk cytogenetics was similar in those receiving first-line therapies or BSC-only; mutations were found in 9.4% of those patients receiving first-line therapies. Median overall survival was 7.36 months for the Argentinean subset vs. 6.2 months for the global cohort. Median progression- free survival was 6.31 (total cohort), 8.05 (HMA), and 1.02 (BSC-only) months. Conclusion: outcomes for unfit patients remain poor, highlighting the unmet need for new therapies and combined regimens.
References
American Cancer Society [Internet]. Key Statistics forAcute Myeloid Leukemia. [citado el 17 de diciembre de 2021]. Disponible en: cancer.org/cancer/acute-myeloid-leukemia/about/key-statistics.html
Palmieri R, Paterno G, De Bellis E y col. Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness. Cancers. 2020; 12(1):120.
National Comprehensive Cancer Network Guidelines [Internet]. Acute Myeloid Leukemia, version 1.2022 [citado el 18 de diciembre de 2021]. Disponible en: https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf
Döhner H, Estey E, Grimwade D y col. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129(4):424-447.
Dombret H, Seymour JF, Butrym A y col. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015; 126(3):291-299.
Ballesteros-Ramírez R, Quijano S, Solano J et al. Influence of Dose Intensity in Consolidation with HIDAC and Other Clinical and Biological Parameters in the Survival of AML. J Cancer Epidemiol. 2020; 2020:8021095.
Miyamoto T, Sanford D, Tomuleasa C et al. Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy. Leuk Lymphoma. 2022; 63(4): 928-938.
Labrador J, Martínez-Cuadrón D, de la Fuente A et al. Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry. Cancers (Basel). 2022; 14(9):2342.
Sociedad Argentina de Hematología [Internet]. AcuteLeukemias, 2019 [citado el 18 de octubre de 2022]. Disponible en: http://www.sah.org.ar/docs/2019/Leucemias_Agudas.pdf
National Comprehensive Cancer Network Guidelines [Internet]. Acute Myeloid Leukemia, version 3.2022 [citado el 13 de enero de 2023]. Disponible en: https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf
Sociedad Chilena de Hematología [Internet]. Myeloblastic Leukemias, 2017 [citado el 19 de octubre de 2022]. Disponible en: https://www.sochihem.cl/bases/arch1730.pdf
Rausch CR, DiNardo CD, Maiti A et al. Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia. Blood 2019; 134 (Supplement_1): 2640.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar